Zacks Investment Research on MSN

Denali enters into a $275M funding deal with Royalty Pharma

Denali Therapeutics Inc. DNLI has announced a funding agreement with Royalty Pharma plc RPRX for $275 million. The stock ...
Fierce Biotech

Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...
Pharmaceutical Technology on MSN

Denali makes $275M funding agreement with Royalty Pharma

Completion of the agreement remains contingent on several closing conditions.

Top Zimbabwe Gold Miner Warns Higher Royalty Would Hit Profits

Caledonia Mining Corp. said a proposal by Zimbabwe’s government to double the royalty on gold producers would curb its ...
The Manila Times

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

XOMA Royalty Corporation ('XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully ...